Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Adrixetinib |
| Trade Name | |
| Synonyms | Q 702|Q-702|Q702 |
| Drug Descriptions |
Adrixetinib (Q702) selectively inhibits Axl, Mertk, and Csf1r, which may relieve immunosuppression in the tumor microenvironment and increase infiltration of immune cells into tumors, potentially leading to tumor regression (AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4974). |
| DrugClasses | AXL Inhibitor 30 CSF1R Inhibitor 28 MERTK Inhibitor 13 |
| CAS Registry Number | 2394874-66-7 |
| NCIT ID | C199002 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Adrixetinib | Adrixetinib | 0 | 2 |
| Adrixetinib + Azacitidine + Venetoclax | Adrixetinib Azacitidine Venetoclax | 0 | 1 |
| Adrixetinib + Pembrolizumab | Adrixetinib Pembrolizumab | 0 | 1 |